MicroRNAs and metabolic disorders – where are we heading?

Śliwińska, Agnieszka; Kasińska, Marta; Drzewoski, Józef

doi:10.5114/aoms.2017.65229

Cited by 43 publications

(35 citation statements)

References 79 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…MiRNAs are master regulators that control many biological processes including cell proliferation, differentiation, apoptosis, and development [ 127 ]. Moreover, they regulate genes involved in metabolic processes such as glucose homeostasis, insulin signaling, pancreatic beta-cell function, lipid metabolism, and inflammation [ 128 ]. Their dysregulation was reported during many metabolic conditions, including obesity, T2D, and cardiovascular disease [ 129 , 130 , 131 ].…”

Section: Micrornasmentioning

confidence: 99%

Molecular Biomarkers for Gestational Diabetes Mellitus

Dias

Pheiffer

Abrahams

et al. 2018

IJMS

View full text Add to dashboard Cite

Gestational diabetes mellitus (GDM) is a growing public health problem worldwide. The condition is associated with perinatal complications and an increased risk for future metabolic disease in both mothers and their offspring. In recent years, molecular biomarkers received considerable interest as screening tools for GDM. The purpose of this review is to provide an overview of the current status of single-nucleotide polymorphisms (SNPs), DNA methylation, and microRNAs as biomarkers for GDM. PubMed, Scopus, and Web of Science were searched for articles published between January 1990 and August 2018. The search terms included “gestational diabetes mellitus”, “blood”, “single-nucleotide polymorphism (SNP)”, “DNA methylation”, and “microRNAs”, including corresponding synonyms and associated terms for each word. This review updates current knowledge of the candidacy of these molecular biomarkers for GDM with recommendations for future research avenues.

show abstract

Section: Micrornasmentioning

confidence: 99%

Molecular Biomarkers for Gestational Diabetes Mellitus

Dias

Pheiffer

Abrahams

et al. 2018

IJMS

View full text Add to dashboard Cite

show abstract

“…There are different theories about obesity's mechanisms, such as inflammation, inflammasome activation, insulin resistance, 2 Arch Med Sci adipokine balance, and abnormalities in lipid metabolism and endothelial function [4]. Some of the newest data have shown that obesity is characterized by low-grade chronic inflammation caused by increased secretion of pro-inflammatory cytokines and adipokines by the macrophages and adipocytes present in adipose tissue [5]. Almost all obese patients should have additional behavioural treatment.…”

Section: Introductionmentioning

confidence: 99%

Safety and efficacy of naltrexone for weight loss in adult patients – a systematic review

2021

View full text Add to dashboard Cite

This is a report of a systematic review of the safety and efficacy of naltrexone or naltrexone/bupropion on weight loss. The databases Medline, PubMed, and Embase as well as the Cochrane Controlled Trials Register for randomized controlled trials were searched for studies published from January 1966 to January 2018. A meta-analysis, randomised controlled trials, controlled trials, uncontrolled trials, cohort studies and open-label studies were analysed. Of 191 articles, 14 fulfilled the inclusion criteria: 1 meta-analysis, 10 randomized controlled trials, and 3 studies without randomization were found. In these studies, the efficacy and safety of naltrexone/bupropion in obesity were analysed. In the majority of these studies, patients with at least 5% or 10% weight loss, as a primary outcome, were investigated. Generally, naltrexone/bupropion treatment can be a promising therapy for obese patients, including when combined with mental health treatment. Based on these studies, it can be said that naltrexone/bupropion treatment is effective in the weight loss of overweight subjects. The naltrexone/bupropion treatment was well tolerated by the patients, and side effects were rarely reported.

show abstract

“…MicroRNAs are a class of small non-coding RNAs, which have been found to have various functions and complicated regulatory mechanisms, and they take part in almost all physiological or pathological cytobiological characteristics, includ ing apoptosis, cell proliferation, and chemotherapy resistance [5][6][7][8]. Some studies have reported that MiRNA-610 was low-expressed in various malignant tumours, including HCC, colorectal cancer, and gastric cancer [9][10][11].…”

Section: Introductionmentioning

confidence: 99%

MiRNA-610 acts as a tumour suppressor to depress the cisplatin resistance in hepatocellular carcinoma through targeted silencing of hepatoma-derived growth factor

Xu¹,

Wang²,

Gao³

2020

aoms

View full text Add to dashboard Cite

Introduction: Hepatic malignancy is one of the most common malignant neoplasms around the globe, and hepatocellular carcinoma (HCC) is the most common type. In this study, the roles and mechanisms of MiRNA-610 in the chemo resistance of HCC will be discussed. Material and methods: The expression of MiRNA-610 and hepatoma-derived growth factor (HDGF) in HCC tissues and cell line was detected by quantitative real-time PCR. The proliferation and chemo resistance were analysed by MTT assay. Flow cytometry was used to examine the apoptosis rate. Luciferase reporter assay was used to verify the correlation between MiRNA-610 and HDGF. HDGF protein expression was detected by Western blot. Results: Our study confirmed the low-expression of MiRNA-610 in HCC tissues and cell line. Its low expression was related to high T stages and poor differentiation of HCC, and was a prognostic factor for HCC. MiRNA-610 upregulation inhibited cell proliferation and induced apoptosis of HepG2 cells. MiRNA-610 enhancement decreased the half maximal inhibitory concentration for cisplatin (DDP) and depressed the DDP resistance in HepG2 cells. The specific correlation between MiRNA-610 and HDGF was tested by luciferase reporter assay and western blot. The transfection with HDGF expression vector up-regulated the expression of HDGF protein silenced by MiRNA-610 enhancement. HDGF overexpression was found to reverse partly the regulatory roles of MiRNA-610 on malignancy and DDP resistance. Conclusions: MiRNA-610 not only played a tumour suppressor role in HCC but also affected chemo resistance to DDP. This role is mainly mediated through targeted silencing of the HDGF gene, which may offer a new potential therapeutic target and improve the clinical therapeutic effect for HCC.

show abstract

MicroRNAs and metabolic disorders – where are we heading?

Cited by 43 publications

References 79 publications

Molecular Biomarkers for Gestational Diabetes Mellitus

Molecular Biomarkers for Gestational Diabetes Mellitus

Safety and efficacy of naltrexone for weight loss in adult patients – a systematic review

MiRNA-610 acts as a tumour suppressor to depress the cisplatin resistance in hepatocellular carcinoma through targeted silencing of hepatoma-derived growth factor

Contact Info

Product

Resources

About